Back to BlackRock, Inc. BlackRock, Inc.

AVXLAVXL
8 quarters

Position history for BlackRock, Inc.BlackRock, Inc.'s holdings in Anavex Life Sciences Corp.

Yes. BlackRock holds 8,055,628 shares of AVXL (Anavex Life Sciences), worth $20.9M, as of its Q2 2026 13F filing. It increased the position by 446,010 shares (+5.9%) from Q1 2026. BlackRock has held AVXL in every 13F on record since Q3 2024, 8 quarterly filings.

Current Value

$20.9M

Current Shares

8.1M

Total Value Change

-$17.4M

Total Shares Change

+1.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
8.1M
+5.9%
$20.9M0.0%$2.59
30
2026-Q1
Increased
7.6M
+1.1%
$23.4M0.0%$3.07
29
2025-Q4
Increased
7.5M
+4.7%
$26.8M0.0%$3.56
30
2025-Q3
Increased
7.2M
+2.7%
$64M0.0%$8.90
30
2025-Q2
Increased
7M
+4.5%
$64.6M0.0%$9.22
31
2025-Q1
Increased
6.7M
+2.3%
$57.5M0.0%$8.58
30
2024-Q4
Decreased
6.6M
-2.8%
$70.4M0.0%$10.74
0
2024-Q3
First report
6.7M
-
$38.3M0.0%$5.68
0

Other major holders of AVXL: State Street Corp., BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used